The latest price target for Athira Pharma (NASDAQ:ATHA) was reported by Mizuho on September 19, 2024. The analyst firm set a price target for $0.50 expecting ATHA to fall to within 12 months (a possible -23.09% downside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Athira Pharma (NASDAQ:ATHA) was provided by Mizuho, and Athira Pharma downgraded their neutral rating.

There is no last upgrade for Athira Pharma

The last downgrade for Athira Pharma Inc happened on September 19, 2024 when Mizuho changed their price target from $5 to $0.5 for Athira Pharma Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Athira Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Athira Pharma was filed on September 19, 2024 so you should expect the next rating to be made available sometime around September 19, 2025.

While ratings are subjective and will change, the latest Athira Pharma (ATHA) rating was a downgraded with a price target of $5.00 to $0.50. The current price Athira Pharma (ATHA) is trading at is $0.65, which is out of the analyst’s predicted range.